UBS Group’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $183K | Sell |
|
|||||
|
2025
Q2 | $363K | Buy |
|
|||||
|
2025
Q1 | $255K | Buy |
|
|||||
|
2024
Q4 | $179K | Buy |
|
|||||
|
2024
Q3 | $304K | Buy |
|
|||||
|
2024
Q2 | $126K | Sell |
|
|||||
|
2024
Q1 | $355K | Sell |
|
|||||
|
2023
Q4 | $200K | Buy |
|
|||||
|
2023
Q3 | $145K | Sell |
|
|||||
|
2023
Q2 | $931K | Buy |
|
|||||
|
2023
Q1 | $417K | Sell |
|
|||||
|
2022
Q4 | $1.77M | Buy |
|
|||||
|
2022
Q3 | $113K | Sell |
|
|||||
|
2022
Q2 | $576K | Sell |
|
|||||
|
2022
Q1 | $1.8M | Sell |
|
|||||
|
2021
Q4 | $3.02M | Buy |
|
|||||
|
2021
Q3 | $1.77M | Buy |
|
|||||
|
2021
Q2 | $485K | Sell |
|
|||||
|
2021
Q1 | $1.29M | Buy |
|
|||||
|
2020
Q4 | $4K | Buy |
|
|||||
|
2020
Q3 | – | Sell |
|
|||||
|
2020
Q2 | $23K | Sell |
|
|||||
|
2020
Q1 | $252K | Sell |
|
|||||
|
2019
Q4 | $364K | Sell |
|
|||||
|
2019
Q3 | $1.66M | Buy |
|
|||||
|
2019
Q2 | $523K | Buy |
|
|||||
|
2019
Q1 | $13K | Sell |
|
|||||
|
2018
Q4 | $2.17M | Buy |
|
|||||
|
2018
Q3 | $1.05M | Buy |
|
|||||
|
2018
Q2 | $565K | Sell |
|
|||||
|
2018
Q1 | $2.25M | Buy |
|
|||||
|
2017
Q4 | $121K | Sell |
|
|||||
|
2017
Q3 | $349K | Buy |
|
|||||
|
2017
Q2 | $12K | Buy |
|
|||||
|
2017
Q1 | $8K | Sell |
|
|||||
|
2016
Q4 | $296K | Buy |
|
|||||
|
2016
Q3 | $71K | Sell |
|
|||||
|
2016
Q2 | $264K | Buy |
|
|||||
|
2016
Q1 | $29K | Sell |
|
|||||
|
2015
Q4 | $912K | Buy |
|
|||||
|
2015
Q3 | $258K | Buy |
|
|||||
|
2015
Q2 | $20K | Buy |
|
|||||
|
2015
Q1 | $9K | Sell |
|
|||||
|
2014
Q4 | $221K | Buy |
|